Andy Chen
Stock Analyst at Wolfe Research
(4.35)
# 341
Out of 5,241 analysts
46
Total ratings
53.33%
Success rate
23.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Initiates: Outperform | $7 | $1.81 | +286.74% | 1 | Apr 9, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $48 | $16.16 | +197.03% | 1 | Apr 9, 2026 | |
| DNTH Dianthus Therapeutics | Initiates: Outperform | $98 | $83.60 | +17.22% | 1 | Apr 9, 2026 | |
| PHVS Pharvaris | Initiates: Outperform | $42 | $28.81 | +45.78% | 1 | Apr 9, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $12 → $24 | $16.44 | +45.99% | 4 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Upgrades: Outperform | $88 | $34.35 | +156.19% | 3 | Mar 11, 2026 | |
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $78.75 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $26.53 | +88.47% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $79.67 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $436.58 | +25.52% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $776.26 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $12.69 | - | 3 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Peer Perform | n/a | $286.27 | - | 3 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $65.32 | -24.98% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $17.01 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $12.95 | +324.71% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.74 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $34.70 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $58.34 | -65.72% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $16.91 | +12.36% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $95.19 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $30.22 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $522.23 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.10 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $72.52 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $48.56 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $28.55 | -40.46% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $107.15 | -60.80% | 1 | Feb 15, 2024 |
Palisade Bio
Apr 9, 2026
Initiates: Outperform
Price Target: $7
Current: $1.81
Upside: +286.74%
Avalo Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $48
Current: $16.16
Upside: +197.03%
Dianthus Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $98
Current: $83.60
Upside: +17.22%
Pharvaris
Apr 9, 2026
Initiates: Outperform
Price Target: $42
Current: $28.81
Upside: +45.78%
MoonLake Immunotherapeutics
Mar 23, 2026
Upgrades: Outperform
Price Target: $12 → $24
Current: $16.44
Upside: +45.99%
Vera Therapeutics
Mar 11, 2026
Upgrades: Outperform
Price Target: $88
Current: $34.35
Upside: +156.19%
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $78.75
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $26.53
Upside: +88.47%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $79.67
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $436.58
Upside: +25.52%
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $776.26
Upside: -
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $12.69
Upside: -
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $286.27
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $65.32
Upside: -24.98%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $17.01
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $12.95
Upside: +324.71%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $58.74
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $34.70
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $58.34
Upside: -65.72%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $16.91
Upside: +12.36%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $95.19
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $30.22
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $522.23
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $16.10
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $72.52
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $48.56
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $28.55
Upside: -40.46%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $107.15
Upside: -60.80%